BRÈVE publiée le 10/11/2025 à 18:10, il y a 7 mois 16 jours Ascend's Innovation Enhances AAV Production Efficiency Gene Therapy Biotechnology Innovation Ascend Advanced Therapies AAV Production Manufacturing Enhancers
BRÈVE publiée le 10/11/2025 à 18:10, il y a 7 mois 16 jours L'innovation d'Ascend améliore l'efficacité de la production d'AAV Thérapie Génique Innovation En Biotechnologie Ascend Advanced Therapies Production AAV Améliorants De Fabrication
COMMUNIQUÉ DE PRESSE publié le 10/11/2025 à 18:05, il y a 7 mois 16 jours Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality Ascend Advanced Therapies unveils proprietary enhancers demonstrating significant improvements in AAV yields and quality attributes for gene therapy programs Ascend Advanced Therapies Proprietary Enhancers AAV Yields Gene Therapy Programs Quality Attributes
BRÈVE publiée le 08/10/2025 à 15:10, il y a 8 mois 18 jours Ascend Advanced Therapies Successfully Defends EpyQ® Patent at EPO Intellectual Property Gene Therapy European Patent Office Ascend Advanced Therapies EpyQ® AAV Plasmid
BRÈVE publiée le 08/10/2025 à 15:10, il y a 8 mois 18 jours Ascend Advanced Therapies défend avec succès le brevet EpyQ® auprès de l'OEB Propriété Intellectuelle Thérapie Génique Office Européen Des Brevets Thérapies Avancées Ascend Plasmide AAV EpyQ®
COMMUNIQUÉ DE PRESSE publié le 08/10/2025 à 15:05, il y a 8 mois 18 jours European Patent on Ascend Advanced Therapies' EpyQ® AAV Plasmid Technology Successfully Defended at the EPO Ascend Advanced Therapies successfully defends European patent EP3722434 for EpyQ® AAV plasmid technology at the EPO, reinforcing its position in gene therapy Gene Therapy European Patent Ascend Advanced Therapies EpyQ® AAV Plasmid Technology
Publié le 26/06/2026 à 17:45, il y a 12 heures 48 minutes Descriptif du programme de rachat d'actions
Publié le 27/06/2026 à 01:40, il y a 4 heures 53 minutes Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Publié le 27/06/2026 à 00:00, il y a 6 heures 33 minutes Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Publié le 26/06/2026 à 23:00, il y a 7 heures 33 minutes Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Publié le 26/06/2026 à 22:50, il y a 7 heures 43 minutes Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Publié le 26/06/2026 à 22:15, il y a 8 heures 18 minutes Revive Therapeutics Announces Proposed Private Placement
Publié le 27/06/2026 à 00:05, il y a 6 heures 28 minutes EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Publié le 27/06/2026 à 00:04, il y a 6 heures 29 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 6 heures 57 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 6 heures 57 minutes EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Publié le 26/06/2026 à 23:27, il y a 7 heures 5 minutes EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
